Upper Aerodigestive Tract Neoplasms
Conditions
Keywords
Upper Aerodigestive Tract Neoplasms, Low-Level Laser Therapy (LLLT), Mucositis
Brief summary
Prospective, monocentric, randomized phase II study evaluating Low-Level Laser Therapy (LLLT) as a treatment for the pain due to grade 2 oral mucositis in patients with upper aero-digestive tract cancer treated by radiotherapy or chemoradiotherapy. Patients with upper aero-digestive tract cancer receiving their first cervicofacial radiotherapy or chemoradiotherapy will be included in this study if they suffer from oral mucositis due to their treatment. The study procedure will consist in 5 applications of the LLLT that will be performed at three days intervals for a maximum duration of 15 days. Each patient will be followed until 3 days after the end of the study treatment, for a total duration of the study of 18 days.
Interventions
DEVICEBasic Oral Care + active LLLT
* Compliance with the Basic Oral Care Associated with * Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
OTHERBasic oral Care + inactive LLLT
* Compliance with the Basic Oral Care Associated with * Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
OTHERBasic Oral Care
Compliance with the Basic Oral Care only
Sponsors
Institut Claudius Regaud
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Patients with upper aero-digestive tract cancer receiving a first cervicofacial radiotherapy or chemoradiotherapy 3. Patients with a grade 2 mucositis (according to the NCI CTCAE version 5.0) appearing during treatment. 4. Patients available to perform the LLLT treatment: 5 visits at 3 days intervals 5. Patients must provide written informed consent prior to any study specific procedures. 6. Patients affiliated to a Social Health Insurance in France.
Exclusion criteria
1. Patients who have already received a cervicofacial radiotherapy 2. Patients who have already received an induction chemotherapy for their upper aero-digestive tract cancer 3. Patients under targeted therapy for their upper aero-digestive tract cancer 4. Patients under systemic corticotherapy 5. Patients with a non-grade 2 mucositis (according to the NCI CTCAE version 5.0) 6. Patients with ulceration or any other oral mucosa pathology than mucositis 7. Pregnant or breastfeeding women 8. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure 9. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients who didn't need a dose increase or introduction of new analgesics for mouth pain during the study compared to baseline | 16 days for each patient |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the oral mucositis pain intensity with Visual Analog Scale Scores | 16 days for each patient |
| Quality of Life assessed by the Quality of Life Questionnaire specific to Head and Neck cancer (H&N35) | 16 days for each patient |
| Frequency of adverse events related to the LLLT using the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) version 5.0 | 16 days for each patient |
Countries
France
Outcome results
None listed